Zacks Investment Research Upgrades Enovis (NYSE:ENOV) to Hold

Enovis (NYSE:ENOVGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, reports.

According to Zacks, “Colfax Corporation is a global supplier of fluid handling products, including pumps, fluid handling systems and specialty valves. Its products serve a variety of applications in the commercial marine, oil and gas, power generation, global navy and general industrial markets and are sold worldwide primarily under the Allweiler, Fairmount, Houttuin, Imo, LSC, Portland Valve, Tushaco, Warren and Zenith brands. “

Shares of ENOV opened at $70.00 on Tuesday. The stock has a market capitalization of $3.76 billion, a P/E ratio of 50.72, a P/E/G ratio of 0.45 and a beta of 2.12. Enovis has a 12-month low of $59.15 and a 12-month high of $164.01. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.49 and a current ratio of 2.25.

About Enovis (Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Featured Articles

Get a free copy of the Zacks research report on Enovis (ENOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with's FREE daily email newsletter.